Astrazeneca Sales Rise 19% On Previous Year; Key New Drugs and Favourable Exchange Rate Help Lift Profits
Linked as:
Summary
ASTRAZENECA, Europe's second-largest drugs maker, continued this week's upbeat trend in the pharmaceutical sector by posting larger- than-expected earnings for the second quarter of the financial year.
The Anglo-Swedish com-pany saw sales rise to $5.29bn ((pounds) 2.86bn) in the second quarter, up 19% against the same period last year. This led to a 24% rise in quarterly pre-tax profits, which in turn helped profits for the first half of the year edge ahead by 1% to $2.25bn.See the full content of this document
Extract
Astrazeneca Sales Rise 19% On Previous Year; Key New Drugs and Favourable Exchange Rate Help Lift Profits
AstraZeneca benefited during the period from increasing sales of newer products, which have been brought on to offset ...
See the full content of this document
Sponsored links
